Tyme Technologies (TYME) Posts Earnings Results, Hits Expectations

Share on StockTwits

Tyme Technologies (NASDAQ:TYME) posted its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08), MarketWatch Earnings reports.

Shares of NASDAQ TYME opened at $3.11 on Tuesday. The company has a market capitalization of $288.93 million, a P/E ratio of -14.81 and a beta of 0.32. Tyme Technologies has a 1 year low of $1.93 and a 1 year high of $4.64.

TYME has been the topic of a number of research analyst reports. BidaskClub upgraded shares of Tyme Technologies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 30th. HC Wainwright set a $10.00 price objective on shares of Tyme Technologies and gave the company a “buy” rating in a report on Friday, January 18th. Finally, Zacks Investment Research lowered shares of Tyme Technologies from a “buy” rating to a “hold” rating in a report on Thursday, January 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Tyme Technologies has an average rating of “Hold” and an average price target of $7.58.

TRADEMARK VIOLATION WARNING: “Tyme Technologies (TYME) Posts Earnings Results, Hits Expectations” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4145734/tyme-technologies-tyme-posts-earnings-results-hits-expectations.html.

About Tyme Technologies

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Read More: How to read a candlestick chart

Earnings History for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Hydro One Ltd  Receives Consensus Rating of “Hold” from Analysts
Hydro One Ltd Receives Consensus Rating of “Hold” from Analysts
Orbis Token  Tops 24 Hour Volume of $0.00
Orbis Token Tops 24 Hour Volume of $0.00
RichCoin Price Up 13.8% Over Last Week
RichCoin Price Up 13.8% Over Last Week
Analysts Expect Osmotica Pharmaceuticals PLC  to Post $0.20 Earnings Per Share
Analysts Expect Osmotica Pharmaceuticals PLC to Post $0.20 Earnings Per Share
CNO Financial Group Inc  Receives Average Recommendation of “Hold” from Brokerages
CNO Financial Group Inc Receives Average Recommendation of “Hold” from Brokerages
indaHash Trading 4.6% Higher  Over Last Week
indaHash Trading 4.6% Higher Over Last Week


Leave a Reply

© 2006-2019 Ticker Report